1.04 USD
↘ 0.04 (3.70%)AT CLOSE (03:59 PM EST)
ALX Oncology Holdings Inc. Common Stock
ALXONASDAQ • USD
1.04
↘ 0.01 (0.48%)
POST MARKET (AS OF 04:14 PM EST)
Post Market
AS OF 04:14 PM EST
1.04
↘ 0.01 (0.48%)
Market: CLOSED
ALX Oncology Holdings Inc. Common Stock (ALXO) trades at $1.04 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest ALXO is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Nov 13, 2026.
Open?$1.11
High?$1.12
Low?$0.94
Prev. Close?$1.08
Volume?673.5K
Avg. Volume?1.3M
VWAP?$1.01
Rel. Volume?0.51x
Bid / Ask
Bid?$0.97 × 1.0K
Ask?$1.18 × 1.5K
Spread?$0.21
Midpoint?$1.08
Valuation & Ratios
Market Cap?143.8M
Shares Out?138.3M
Float?92.2M
Float %?66.7%
P/E Ratio?N/A
P/B Ratio?1.06
EPS?-$0.58
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Employees
48
Market Cap
143.8M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2020-07-17
Address
323 ALLERTON AVENUE
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-466-7125
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-466-7125
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?65
Short Sent.?49
Piotroski F-Score?0/9Weak
Altman Z-Score?-3.84Distress
Confidence?49%Low
Short InterestElevated
Short % of Float?6.69%Elevated
Short Interest?6.2M
Days to Cover?4.4
Free Float92.2M
Avg Daily Volume1.4M
Settlement Date2026-10-30
Financial Health
Current Ratio?9.71Strong
Quick Ratio?9.71Strong
Cash Ratio?1.54Strong
Debt/Equity?0.07Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?1.06CHEAP▾
Peers100
S&P97
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-1.6CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-59.4%WEAK▾
S&P3
ROA?-50.3%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-70950000
Enterprise Value?$130.8M
Fundamentals ratios updated end of day